Nanjing Chia-Tai Tianqing Pharmaceutical

Clinical trials sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical, explained in plain language.

Now part of Sino Biopharmaceutical Limited 1177 HKEX

A Chinese pharmaceutical company developing and commercializing drugs, a subsidiary of CTTQ.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New pill could replace infusions for rare blood disorder Results expected Nov 2026 (estimated)
New drug NTB003 aims to reduce bulging eyes in thyroid disease Results expected May 2027 (estimated)

Browse trials soon ready across all sponsors →

Not yet recruiting 4 Not yet finished but already full! 2 Completed 1

New drug could ease endometriosis pain in major trial

Symptom relief Completed

This phase 3 trial tested the drug elagolix in 202 women with moderate to severe pain from endometriosis. Participants took either elagolix or a placebo for 12 weeks. The study measured how well the drug reduced menstrual cramps and pelvic pain. The goal is to see if elagolix can…

Phase 3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Symptom relief

Last updated Jun 27, 2026 07:51 UTC

Nanjing Chia-Tai Tianqing Pharmaceutical

Upcoming readouts

New drug could ease endometriosis pain in major trial